The objective of this work is the discovery of 2',3'-dideoxynucleosides (DDO) which are superior to known inhibitors of the HTLV-III virus. DDO-5-azacytidine was active but somewhat more toxic than DDO-C. The 5-fluoro analog of DDO-C was just as effective and potent as the parent compound in protecting HTLV-III infected cells. However, the 5-bromo and 5-methyl analogs were ineffective. DDO-cyclopentenyl isosteres (neplanocin analogs) proved to be inactive and nontoxic.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Intramural Research (Z01)
Project #
1Z01CM006173-01
Application #
3963220
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Cancer Treatment
Department
Type
DUNS #
City
State
Country
United States
Zip Code